In an update medical policy, Anthem said it will cover the test every three years for certain patients for whom the test is considered medically necessary.
The firm plans to offer 5,350,000 shares of its common stock at a price between $13 and $15 per share.
The New York Times reports on an effort to address in high school biology classes misconceptions regarding race and genetics.
60 Minutes speaks with Harvard's George Church about tackling the effects of aging and more.
In PLOS this week: rare alterations in Timothy syndrome, analysis of twins' gut microbiomes, and more.
GenomeWeb reports that Veritas Genetics is suspending its US operations.
